ArticleJournal of fungi (Basel, Switzerland)2020
Azole-Resistant COVID-19-Associated Pulmonary Aspergillosis in an Immunocompetent Host: A Case Report.
Article in Journal of fungi (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 72 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
72 citing papers in PubMed, 2 syntheses or guidelines pooled it, 108 citations in OpenAlex.
- CT findings of COVID-19-associated pulmonary aspergillosis: a systematic review and individual patient data analysis.Clinical imaging · 2022Pooled it
- Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): a systematic review.The Journal of hospital infection · 2021Pooled it
- Global epidemiology of azole resistance inJAC-antimicrobial resistance · 2026Review
- Review
- Molecular Identification ofInfection and drug resistance · 2025Article
- Structures of trehalose-6-phosphate synthase, Tps1, from the fungal pathogenProceedings of the National Academy of Sciences of the United States of America · 2024Article
- Coronavirus disease 2019 (COVID-19)-associated brain abscesses caused by Pseudomonas aeruginosa and Aspergillus fumigatus: two case and a review of the literature.Journal of medical case reports · 2023Review
- Microbiological profile of multidrug resistant bacteria before and during COVID-19 in CHU Mohammed VI.Iranian journal of microbiology · 2023Article
- Genomic Epidemiology Identifies Azole Resistance Due to TRJournal of fungi (Basel, Switzerland) · 2023Article
- Secondary fungal infections in SARS-CoV-2 patients: pathological whereabouts, cautionary measures, and steadfast treatments.Pharmacological reports : PR · 2023Review
- Use of data mining approaches to explore the association between type 2 diabetes mellitus with SARS-CoV-2.BMC pulmonary medicine · 2023Article
- COVID-19 associated mold infections: Review of COVID-19 associated pulmonary aspergillosis and mucormycosis.Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi · 2023Review
- Managing the Next Wave of Influenza and/or SARS-CoV-2 in the ICU-Practical Recommendations from an Expert Group for CAPA/IAPA Patients.Journal of fungi (Basel, Switzerland) · 2023Article
- Pathogenic Drug Resistant Fungi: A Review of Mitigation Strategies.International journal of molecular sciences · 2023Review
- Telomere-to-telomere genome sequence of the model mould pathogen Aspergillus fumigatus.Nature communications · 2022Article
- The importance of antimicrobial resistance in medical mycology.Nature communications · 2022Review
- Comparative risk assessment of COVID-19 associated mucormycosis and aspergillosis: A systematic review.Health science reports · 2022Article
- Aspergillus-specific IgM/IgG antibody serostatus of patients hospitalized with moderate-critical COVID-19 in Uganda.African health sciences · 2022Article
- Tendency in Pulmonary Aspergillosis Investigation during the COVID-19 Era: What Is Changing?International journal of environmental research and public health · 2022Article
- Invasive pulmonary aspergillosis in critically ill patients with pneumonia due to COVID-19, influenza, and community-acquired pneumonia: A prospective observational study.Current medical mycology · 2022Article
12 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19-associated pulmonary aspergillosis (CAPA) is a recently described disease entity affecting patients with severe pulmonary abnormalities treated in intensive care units. Delays in diagnosis contribute to a delayed start of antifungal therapy. In addition, the emergence of resistance to triazole antifungal agents puts emphasis on early surveillance for azole-resistant
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.